Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2005

View Archived Issues

FR-255031 prevents progression of joint destruction in arthritic rats

Nonimmunosuppressive immunophilin FK-1706 potentiates neurite outgrowth in vitro

Novel therapeutic strategy for heart failure effective in dogs

New data on the pharmacokinetics of roflumilast in pediatric patients

Clinical evidence supports the use of TroVax in metastatic colorectal cancer

Clinical evaluation of prasugrel as inhibitor of platelet aggregation

Flamel Technologies terminates Genvir license agreement with Biovail

SPA agreement for pivotal study of INO-1001

New phase I/II study evaluates Amplimexon plus gemcitabine

HEALOS(R)-MP52 advantageous in treating long bone defects

Istradefylline maintains efficacy in Parkinson's disease over one year

Coenzyme Q10 use remains limited in Parkinson's disease outpatients

In vivo efficacy of combined warfarin/probucol therapy for steroid-induced osteonecrosis

Chinese clinical program progresses for Calypte's HIV-1/2 tests

Senexis and BioFocus to develop novel small-molecule drugs for Alzheimer's

Pivotal trial brought forward for phenoxodiol for chemoresistant ovarian cancer

Remodulin receives the first European approval in France

Enrollment reaches half way in phase III HIV prevention study of Savvy

Promising findings for VNS Therapy in bulimia nervosa

New Melanotan trials cleared to begin in Australia and Finland

Tsumura discontinues development of TJN-598

Org-24461 reverses negative symptoms of schizophrenia in preclinical models / News in Context

Seletracetam reduces levodopa-induced dyskinesia in marmosets

Induction of HSP70 produces neuroprotective effects

Indoleamine 2,3-dioxygenase inhibitors improve chemotherapy / News in Context

Novel cathepsin S inhibitors disclosed by IRM

HIV reverse transcriptase inhibitors discovered at the University of Illinois

Galderma discloses new PPARgamma receptor agonists

HER (erbB) family kinase inhibitors for the treatment of cancer reported by GSK

Merck claims new KSP inhibitors and their use in treating cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.